相关实验视频
Updated: Jun 12, 2025

11:07
Focal Laser Ablation of Prostate Cancer: An Office Procedure
Published on: March 30, 2021
7.8K
前列腺癌焦点治疗:外科医生经验影响瘤学结果
Claudio Bovolenta Murta1, José Pontes Júnior1, Pedro Humberto Felix de Souza Filho2
1Urology Department, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.
The Prostate
|September 27, 2024
概括
外科医生的经验显著影响前列腺癌 (PCa) 焦点治疗结果. 经验较少的外科医生与更高的激进治疗和焦点治疗失败率有关,这突显了高强度聚焦超声波 (HIFU) 程序的专业知识的重要性.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 医疗技术 医疗技术 医学技术
背景情况:
- 前列腺癌的焦点治疗 (PCa) 旨在尽量减少与激进治疗相关的并发症.
- 描述指数损伤对于开发有效的焦点治疗策略至关重要.
研究的目的:
- 确定与PCa焦点治疗后的瘤结果相关的因素.
- 评估外科医生经验对治疗成功的影响.
主要方法:
- 123名PCa患者在2017年4月至2020年2月期间使用高强度聚焦超声波 (HIFU) 进行了焦点治疗.
- 患者患有单边局部性疾病,PSA<20 ng/dl,临床阶段T1-T2.2.
- 根据经验分组外科医生:第1组/第2组 (>30个HIFU) 和第3组 (10-15个HIFU).
- 随访包括1年后的监测活检;终点是激进治疗,焦点治疗失败和现场复发.
- 单变量和多变量逻辑回归分析了临床/程序变量和结果之间的关联.
主要成果:
- 随访时间中位数为54.3个月. 23.6%需要彻底治疗,30.1%经历治疗失败,21.1%在现场复发 (ISUP等级≥2).
- 激进治疗与第三组外科医生和HIFU后PSA升高有关.
- 与基线PSA,第三组外科医生和HIFU后PSA相关的治疗失败.
- 实地阳性活检与基线和HIFU后PSA相关.
- 第三组的外科医生独立地与激进治疗和焦点治疗失败有关.
结论:
- 使用HIFU的焦点治疗表明局部PCa的可接受的中期瘤结果.
- 外科医生的经验和技术是对后续激进治疗和焦点治疗失败的需要的独立预测因素.
- 优化焦点治疗方案可能包括考虑外科医生的专业知识,以改善患者的治疗结果.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Survival Analysis
331
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
331

